12 weeks of a Ribavirin-free Sofosbuvir and NS5A inhibitor regimen is enough to treat recurrence of hepatitis C after liver transplantation

Pauline Houssel-Debry 1 Audrey Coilly 2, 3 Claire Fougerou-Leurent 4, 1 Caroline Jezequel 1 Christophe Duvoux 5 Victor de Ledinghen 6 Sylvie Radenne 7 Nassim Kamar 8 Vincent Leroy 9 Vincent Di Martino 10 Louis d'Alteroche 11 Valérie Canva Filomena Conti Jerome Dumortier Hélène Montialoux 12 Pascal Lebray Danielle Botta-Fridlund Albert Tran Christophe Moreno 13 Christine Silvain 14 Camille Besch Philippe Perre Claire Francoz 15 Armando Abergel 16 François Habersetzer 17 Maryline Debette-Gratien 18 Carole Cagnot 19, 20 Alpha Diallo 20, 19 Stéphane Chevaliez Emilie Rossignol 4, 1 Aurelie Veislinger 4 Jean-Charles Duclos-Vallee 2, 3 Georges-Philippe Pageaux
Abstract : Sofosbuvir (SOF) combined with NS5A inhibitors has demonstrated its efficacy in treating a recurrence of HCV after liver transplantation. However, the duration of treatment and the need for ribavirin (RBV) remain unclear in this population. Our aim was to determine whether liver transplant recipients could be treated with an SOF+NS5A inhibitor-based regimen without RBV for 12 weeks after liver transplantation (LT).
Document type :
Journal articles
Complete list of metadatas

https://hal-univ-rennes1.archives-ouvertes.fr/hal-01807755
Contributor : Laurent Jonchère <>
Submitted on : Tuesday, June 5, 2018 - 10:25:47 AM
Last modification on : Friday, November 8, 2019 - 10:52:30 AM

Links full text

Identifiers

Citation

Pauline Houssel-Debry, Audrey Coilly, Claire Fougerou-Leurent, Caroline Jezequel, Christophe Duvoux, et al.. 12 weeks of a Ribavirin-free Sofosbuvir and NS5A inhibitor regimen is enough to treat recurrence of hepatitis C after liver transplantation. Hepatology, Wiley-Blackwell, 2018, 68 (4), pp.1277-1287. ⟨10.1002/hep.29918⟩. ⟨hal-01807755⟩

Share

Metrics

Record views

134